Clinical Trial Update: Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating oral nintedanib for epistaxis in hereditary hemorrhagic telangiectasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Telangiectasia, Hereditary Hemorrhagic, Rendu Osler Disease | Phase 2 | Status: COMPLETED